170 related articles for article (PubMed ID: 9067284)
1. Identification of constitutive and gamma-interferon- and interleukin 4-regulated proteins in the human renal carcinoma cell line ACHN.
Sullivan CM; Smith DM; Matsui NM; Andrews LE; Clauser KR; Chapeaurouge A; Burlingame AL; Epstein LB
Cancer Res; 1997 Mar; 57(6):1137-43. PubMed ID: 9067284
[TBL] [Abstract][Full Text] [Related]
2. Manganese superoxide dismutase is induced by IFN-gamma in multiple cell types. Synergistic induction by IFN-gamma and tumor necrosis factor or IL-1.
Harris CA; Derbin KS; Hunte-McDonough B; Krauss MR; Chen KT; Smith DM; Epstein LB
J Immunol; 1991 Jul; 147(1):149-54. PubMed ID: 1904900
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta.
Dansky-Ullmann C; Salgaller M; Adams S; Schlom J; Greiner JW
Cytokine; 1995 Feb; 7(2):118-29. PubMed ID: 7780031
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors.
Raitano AB; Korc M
Cancer Res; 1993 Feb; 53(3):636-40. PubMed ID: 8425199
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide.
Aune TM; Pogue SL
J Clin Invest; 1989 Sep; 84(3):863-75. PubMed ID: 2503544
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.
Hoon DS; Okun E; Banez M; Irie RF; Morton DL
Cancer Res; 1991 Oct; 51(20):5687-93. PubMed ID: 1913686
[TBL] [Abstract][Full Text] [Related]
8. [Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay--single and combination effect with cancer chemotherapeutic agent].
Ohmura K; Tsukamoto T
Hinyokika Kiyo; 1989 May; 35(5):737-47. PubMed ID: 2801371
[TBL] [Abstract][Full Text] [Related]
9. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients.
Bae SM; Lee CH; Cho YL; Nam KH; Kim YW; Kim CK; Han BD; Lee YJ; Chun HJ; Ahn WS
Gynecol Oncol; 2005 Oct; 99(1):26-35. PubMed ID: 16051329
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma downregulates Hsp27 expression and suppresses the negative regulation of cell death in oral squamous cell carcinoma lines.
Yonekura N; Yokota S; Yonekura K; Dehari H; Arata S; Kohama G; Fujii N
Cell Death Differ; 2003 Mar; 10(3):313-22. PubMed ID: 12700631
[TBL] [Abstract][Full Text] [Related]
11. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues.
Perego RA; Bianchi C; Corizzato M; Eroini B; Torsello B; Valsecchi C; Di Fonzo A; Cordani N; Favini P; Ferrero S; Pitto M; Sarto C; Magni F; Rocco F; Mocarelli P
J Proteome Res; 2005; 4(5):1503-10. PubMed ID: 16212400
[TBL] [Abstract][Full Text] [Related]
12. Modulation of interferon receptor expression during combination beta ser-interferon and gamma-interferon treatment of human colon carcinoma cells.
Schiller JH; Bushmeyer SM; Ruzicka FJ; Princler GL; Faltynek CR; Borden EC
Cancer Res; 1990 Jan; 50(1):26-31. PubMed ID: 2136700
[TBL] [Abstract][Full Text] [Related]
13. The role of interferon regulatory factor-1 in cytokine-induced mRNA expression and cell death in murine pancreatic beta-cells.
Pavlovic D; Chen MC; Gysemans CA; Mathieu C; Eizirik DL
Eur Cytokine Netw; 1999 Sep; 10(3):403-12. PubMed ID: 10477397
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
15. Differential protein profiling in renal-cell carcinoma.
Shi T; Dong F; Liou LS; Duan ZH; Novick AC; DiDonato JA
Mol Carcinog; 2004 May; 40(1):47-61. PubMed ID: 15108329
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of polypeptides by tumor necrosis factor and interferon-gamma in cells sensitive or resistant to tumor necrosis factor: assessment by computer based analysis of two-dimensional gels using the PDQUEST system.
Beresini MH; Sugarman BJ; Shepard HM; Epstein LB
Electrophoresis; 1990 Mar; 11(3):232-41. PubMed ID: 2111772
[TBL] [Abstract][Full Text] [Related]
17. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
Fehniger TA; Shah MH; Turner MJ; VanDeusen JB; Whitman SP; Cooper MA; Suzuki K; Wechser M; Goodsaid F; Caligiuri MA
J Immunol; 1999 Apr; 162(8):4511-20. PubMed ID: 10201989
[TBL] [Abstract][Full Text] [Related]
18. Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2.
Rasmussen RK; Ji H; Eddes JS; Moritz RL; Reid GE; Simpson RJ; Dorow DS
Electrophoresis; 1997; 18(3-4):588-98. PubMed ID: 9150946
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
20. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
